Skip to content

Q BIOMED INC.: 10-Q filed 2019-07-19

What Q BIOMED INC. reported in its quarterly report filed 2019-07-19 (fiscal Q2 2019): 22 published measures, 59 facts as tagged in accession 0001144204-19-035232.

This filing

Form
10-Q (quarterly report)
Filed
2019-07-19
Fiscal period
fiscal Q2 2019
Accession
0001144204-19-035232 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Q BIOMED INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-05-31682,261USD
At 2018-11-303,196,913USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-05-315,042,737USD
At 2018-11-303,302,641USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-05-31-4,360,476USD
At 2019-02-28-1,997,035USD
At 2018-11-30-105,728USD
At 2018-05-311,886,379USD
At 2018-02-283,619,197USD
At 2017-11-30356,244USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-05-31178,715USD
At 2018-11-302,684,413USD
At 2018-05-312,324,171USD
At 2017-11-30824,783USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-03-01 to 2019-05-31-2,888,147USD92
2018-12-01 to 2019-05-31-5,263,229USD182
2018-03-01 to 2018-05-31-2,012,804USD92
2017-12-01 to 2018-05-31-4,186,983USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-12-01 to 2019-05-31-2,586,448USD182
2017-12-01 to 2018-05-31-3,445,863USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-12-01 to 2019-05-3180,750USD182
2017-12-01 to 2018-05-314,945,251USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-05-31-37,377,376USD
At 2018-11-30-32,114,147USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-12-01 to 2019-05-311,008,481USD182
2017-12-01 to 2018-05-31771,867USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-05-31207,261USD
At 2018-11-302,696,913USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-03-01 to 2019-05-31369,972USD92
2018-12-01 to 2019-05-31660,644USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-05-311,373,125USD
At 2018-11-30429,369USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2019-05-31475,000USD
At 2018-11-30500,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-03-01 to 2019-05-312,267,175USD92
2018-12-01 to 2019-05-314,324,585USD182
2018-03-01 to 2018-05-312,012,804USD92
2017-12-01 to 2018-05-314,186,983USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-03-01 to 2019-05-311,071,416USD92
2018-12-01 to 2019-05-311,886,115USD182
2018-03-01 to 2018-05-31782,188USD92
2017-12-01 to 2018-05-311,635,613USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-05-3114,677,136shares
At 2018-11-3014,290,236shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-05-3133,002,224USD
At 2018-11-3031,994,129USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2019-05-313,669,612USD
At 2018-11-302,873,272USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2019-05-3180,750USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-03-01 to 2019-05-31-2,888,147USD92
2018-12-01 to 2019-05-31-5,263,229USD182
2018-03-01 to 2018-05-31-2,012,804USD92
2017-12-01 to 2018-05-31-4,186,983USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-03-01 to 2019-05-311,195,759USD92
2018-12-01 to 2019-05-312,438,470USD182
2018-03-01 to 2018-05-311,230,616USD92
2017-12-01 to 2018-05-312,551,370USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-12-01 to 2019-05-31720,861USD182
2017-12-01 to 2018-05-31-30,747USD182

Inspect the source

Entity
Q BIOMED INC. / CIK 0001596062
Captured
SEC response SHA-256
f89c4e51720d8de34ddffc303f833ea01697bd4742662935a9f3cf09e3e7efbc

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001596062.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))